How rival weight-loss drugs fare at treating obesity, diabetes and more Trials for Eli Lilly’s triple-action drug, retatrutide, will continue throughout 2025. In its phase II trial, retatrutide ...

Eli Lilly is now developing another drug, retatrutide, and the latest data suggests it may be even more effective for weight ...

Retatrutide is a once-weekly injection from pharmaceutical company Eli Lilly, which is in the process of completing phase 2 trials to study the drug for both weight loss and managing type 2 diabetes.